This week in Other Barks & Bites: the U.S. Copyright Office issues its final rule on agency fees reducing proposed fee increases for certain group registrations and paper notices of termination; Anthropic stock falls 10% the day after its IPO as part of a bad week for tech stocks; the Sixth Circuit affirms the cancellation of trademark damages as an impermissible double recovery in a trade secret case against Ford; and more.
The U.S. Court of Appeals for the Federal Circuit (CAFC), in two rulings issued today in Touchmusic Entertainment LLC v. Netflix, Inc. and Touchmusic Entertainment LLC v. Apple Inc. and Amazon Web Services, Inc., affirmed decisions of the U.S. District Court for the Northern District of Illinois dismissing infringement claims Ziklag IP LLC asserted on an expired patent. In the Netflix appeal, the CAFC found no abuse of discretion in the district court’s refusal to allow Ziklag to return the original patent owner, Touchmusic, to the case. In the two appeals involving Apple and Amazon Web Services, Inc. (AWS), the CAFC held that Ziklag was collaterally estopped from contesting a ruling that it never received the right to sue for past damages.
U.S. Supreme Court opinions in Mayo Collaborative Services v. Prometheus Laboratories, Inc., Association for Molecular Pathology v. Myriad Genetics, Inc., and Alice Corporation Pty. Ltd. V. CLS Bank International et al., produced significant challenges to and unpredictability in obtaining and enforcing patent protection in areas including precision medicine, diagnostics, AI, and pharmaceutical treatments. The Patent Eligibility Restoration Act of 2025 (PERA), S. 1546 and the identical H.R. 3152, seek to address these challenges by rewriting 35 U.S.C. § 101 to eliminate all of these “judicial exceptions to patent eligibility.”
You Can See Everything is a thought-provoking amalgam of fact, flare and creative personality profiling inventor Elizabeth Holmes and her partner, Billy Evans, as she prepares for an 11-year prison sentence for defrauding high-profile investors. While her name is associated with more than 150 patents, it is unclear exactly what she invented and the nature of the value it has generated.
This week on IPWatchdog Unleashed, we discuss how a credible trial preparation supports settlement leverage. From the in-house vantage point, a litigation team’s ability to articulate a persuasive case matters even when the preferred outcome is an early resolution. For patent owners, accused infringers, and the counsel advising them, this conversation highlights why audience awareness, technical clarity, and case development belong within the same strategy. The episode offers a substantive look at how experienced practitioners make those judgments—and how the choices made throughout a case shape both courtroom advocacy and the options available outside it.
Uncertainty in patent rights undermines the investment needed to turn scientific breakthroughs into commercial products—but accepting that uncertainty is a choice. In this episode of IPWatchdog Unleashed, Judge Pauline Newman draws on her experience in industry and the policy discussions that helped shape the Federal Circuit to connect today’s life sciences challenges with the conditions that drove an earlier era of patent reform. She explains why predictable, reliable patent protection matters to research investment, commercialization, and the ability to recover the costs of failed research as well as successful discoveries. Her message to IP counsel, industry leaders, and policymakers is direct: addressing the weaknesses of the patent system requires looking beyond how to navigate existing law and engaging in the work of changing it.
This week on IPWatchdog Unleashed, we have a discussion about the IP risks associated with AI use and adoption, with Stephanie Curcio, Marlene Valderrama, Kendra Ervin and Rinat Shangeeta. The discussion reveals a consequential gap with how businesses are deploying AI. Many companies are moving faster to adopt AI than their governance, contracting and IP review processes can accommodate. For those responsible for protecting innovation and confidential information, the challenge is ensuring that enthusiasm for AI adoption does not obscure the consequences of how these tools are actually used.
For foreign companies holding trademarks, patents, industrial designs, or other intellectual property assets in Brazil, detecting an infringement can trigger an almost automatic reaction: filing a lawsuit. Although resorting to the courts is an important tool for protecting intellectual property rights, it does not necessarily need to be the first step.
This week on IPWatchdog Unleashed, I spoke with Emily Johnson, Nicholas Lanzatella, Kwame Mensah, and Corey Salsberg. This conversation took place on November 9, 2026, at IPWatchdog Studios at the fifth annual Life Sciences Masters™ conference. We examine how artificial intelligence is changing life sciences research and patent strategy. Our focus was on the emergence of super-fast followers, who are competitors positioned to quickly analyze published inventions and rapidly pursue related candidates and patent filings. For an industry built on expensive, uncertain research, the implications reach well beyond faster drafting or more efficient discovery. At stake is the balance between accelerating the development of new medicines and preserving the economic incentives that make pioneering discoveries possible in the first place.
The U.S. Court of Appeals for the Federal Circuit (CAFC) on Wednesday vacated a judgment of no infringement and affirmed a validity finding for patent owner Edge Systems LLC. The nonprecedential opinion was authored by Judge Prost and joined by Judges Hughes and Cunningham.
This week on IPWatchdog Unleashed, I spoke with Emily Johnson, Nicholas Lanzatella, Kwame Mensah, and Corey Salsberg. This conversation took place on November 9, 2026, at IPWatchdog Studios at the fifth annual Life Sciences Masters™ conference. We examine how artificial intelligence is changing life sciences research and patent strategy. Our focus was on the emergence of super-fast followers, who are competitors positioned to quickly analyze published inventions and rapidly pursue related candidates and patent filings. For an industry built on expensive, uncertain research, the implications reach well beyond faster drafting or more efficient discovery. At stake is the balance between accelerating the development of new medicines and preserving the economic incentives that make pioneering discoveries possible in the first place.
The USPTO deserves some credit for recognizing that applicants may at times need an opportunity to explain technical improvements that examiners have failed to appreciate, but there is real risk associated with filing a SMED that should cause practitioners to pause rather than race forward without serious consideration. And despite some difference of opinion, we all agreed on an essential point: Filing a SMED should not be the first line of defense against an eligibility rejection; it should should be treated as a last resort. Filing a SMED requires serious consideration of the advantages, disadvantages, and alternatives. Examiner interviews, arguments grounded in the existing specification, appropriate claim amendments, and appeals all deserve careful consideration before ever adding sworn statements to the prosecution history. The question must be whether the declaration supplies something genuinely necessary to advance the case, and even then must be intentionally specific and narrow.
A patent’s economic value and the price it commands in a licensing negotiation can be very different things. The technology may deliver substantial commercial benefits, yet the amount a patent owner can capture depends on legal risk, enforcement costs, negotiating leverage, and each party’s business objectives. This week on IPWatchdog Unleashed, we ask how much a patent is really worth, and how to prove it at a negotiating table or in court. This conversation, which occurred as part of IPWatchdog’s 2026 Women’s IP Forum, examines how sophisticated licensors, licensees, counsel, and valuation professionals assess patent value in real-world transactions and disputes. The conversation explored royalty structures, comparable licenses, portfolio strength, litigation and validity risk, damages principles, standard-essential patent (SEP) licensing, and the practical factors that drive parties toward—or away from—a deal.
This is the best way to stay informed. We send a daily roundup of our latest news, press releases, and events.
Get Email Updates